Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C- mutant lacking a drug resistance marker in the pigs
Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C- mutant lacking a drug resistance marker in the pigs
复制标题
缺乏耐药标记的胸膜肺炎放线杆菌HB04C(-)突变体对猪的免疫原性和保护功效评价。
DOI：
10.1016/j.vetmic.2007.05.013
复制
发表时间：
2007-11-15
影响因子：
3.3
通讯作者：
Chen, Huanchun
中科院分区：
文献类型：
--
作者：
Bei, Weicheng;He, Qigai;Chen, Huanchun
在此之前，我们报道了一个基因定义的胸膜肺炎放线杆菌（A。pleuropneumoniae）apxIIC基因突变体141304 C（-），对小鼠抗A.胸膜肺炎在本研究中，我们进一步评估了HB 04 C（-）的安全性及其在猪中引发保护性免疫的能力。经证明，2 x 108 CFU HB 04 C（-）剂量通过鼻内或肌内注射对猪是安全的。通过鼻内和肌内常规接种2 x 108 HB 04 C-剂量的免疫可产生相同的保护效力，并对用同源或异源血清型强毒A的实验攻击产生显著保护。胸膜肺炎综上所述，HB 04 C-有可能成为抗A.胸膜肺炎(C)2007 Elsevier B. V.保留所有权利。
Previously, we reported the construction and characterization of a genetically defined Actinobacillus pleuropneumoniae (A. pleuropneumoniae) apxIIC gene mutant, 141304C(-), which conferred protection to mice against infection with A. pleuropneumoniae. In this study, we further evaluated HB04C(-) for safety and its ability to elicit protective immunity in pigs. It was demonstrated that a dose of 2 x 108 CFU HB04C(-) was safe to the pigs via intranasal or intramuscular injection. Immunization with a dose of 2 x 108 HB04C- by both intranasal and intramuscular routine could yield equal protective efficacy and elicited significant protection against experiment challenge with homologous or heterologous serotypes of a virulent A. pleuropneumonia. Taken together, HB04C- might serve as a promising vaccine candidate against infection with A. pleuropnetanoniae. (C) 2007 Elsevier B.V. All rights reserved.